LRMR

Larimar Therapeutics, Inc. (LRMR)
Healthcare • Biotechnology • $3.83 • MCap: 397,871,648 🌐
https://www.larimartx.com • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Buy Decision Core
Total Score
30
Business Quality
1
Financial Strength
10
Growth Outlook
1
Momentum
2
Price Action
Current
3.83
52W High
5.95
52W Low
2.81
Above 50DMA
3.90 (-1.80%)
Above 200DMA
3.93 (-2.59%)
Relative Strength
Relative Strength
0.05
RS 3M
0.21
RS 6M
-0.27
RS 9M
0.1
RS 12M
-0.01
Fundamentals
Revenue Growth
0%
Earnings Growth
0%
ROE
-1.40%
ROA
-0.71%
Valuation
PE (Fwd)
-3.61
PEG
0
P/B
3.14
Upside
273.37%
Risk
Beta
0.75
Short %
0.20
Risk Score
8.00
Analyst
Rating
none
Target
14.30
Beta
0.75
Analysts
0
Total Score
30
Upside
273.37%
Relative Strength
0.05
Beta
0.75
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Analyst upside exceeds 15%
Key Risks
  • Negative ROE
  • Weak long-term relative strength
Score Breakdown
Business
1
Financial
10
Growth
1
Valuation
11
Risk
3
Momentum
2
Technical
52W High: 5.95
52W Low: 2.81
Above 50DMA: -1.80%
Above 200DMA: -2.59%
Valuation
Forward PE: -3.61
PEG: 0
P/B: 3.14
Upside: 273.37%
Risk
Beta: 0.75
Short Float: 0.20%
ROE: -1.40%
ROA: -0.71%